Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation

Bibliography

• Rowland AS, Lesesne CA, Abramowitz AJ. The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Ment Retard Dev Disabil Res Rev 2002;8:162-70
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition. Text revision (DSM-IV-TR) American Psychiatric Association, Washington, DC; 2013
   Google Scholar
• Academic highlights update section of The Primary Care Companion to The Journal of Clinical Psychiatry. Assessing adults with ADHD and comorbidities. Prim care Companion. J Clin Psychiatry 2009;11:25
   Google Scholar
• Dell’Agnello G, Zuddas A, Masi G, et al. Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions. CNS Drugs 2009;23:739-53
   PubMed Web of Science ®Google Scholar
• Young J. Common comorbidities seen in adolescents with attention-deficit/hyperactivity disorder. Adolesc Med State Art Rev 2008;19:216-28
   PubMedGoogle Scholar
• Young S, Amarasinghe JM. Practitioner review: non-pharmacological treatments for ADHD: a lifespan approach. J Child Psychol Psychiatry 2010;51:116-33
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Steeves T. Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev 2011;CD007990
   Google Scholar
• Harrison JN, Cluxton-Keller F, Gross D, et al. Antipsychotic medication prescribing trends in children and adolescents. J Pediatr Health Care 2012;26:139-45
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 2009;11:203-26
   PubMedGoogle Scholar
• Wietecha LA, Ruff DD, Allen AJ, et al. Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies. J Clin Psychiatry 2013;74:1217-23
   PubMed Web of Science ®Google Scholar
• Vetter VL, Elia J, Ericksdon C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008;117:2407-23
   PubMed Web of Science ®Google Scholar
• Gong S, Sheng P, Jin H, et al. Effect of methylphenidate in patients with cancer-related fatigue: a systematic review and meta-analysis. PLoS One 2014;9:e84391
   PubMed Web of Science ®Google Scholar
• Roesch B, Corcoran M, Haffey M, et al. Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release. Drugs R D 2013;13:53-61
   PubMedGoogle Scholar
• Graham J, Banaschewski T, Buitelaar J, et al. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 2011;20:17-37
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP) Annex I—Definitions (Rev 3). 2012
   Google Scholar
• Bushe CJ, Savill NC. Suicide related events and attention deficit hyperactivity disorder treatments in children and adolescents: a meta-analysis of atomoxetine and methylphenidate comparator clinical trials. Child Adolesc Psychiatry Ment Health 2013;7:19
   PubMedGoogle Scholar
• Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008;47:209-18
   PubMed Web of Science ®Google Scholar
• Panei P, Arcieri R. ADHD register: post-marketing evaluation of the benefit-risk profile of drugs and promotion of the appropriateness. Recenti Prog Med 2013;104:254-61
   PubMedGoogle Scholar
• Ruggiero S, Rafaniello C, Bravaccio C, et al. Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. J Child Adolesc Psychopharmacol 2012;22:415-22
   PubMed Web of Science ®Google Scholar
• Paxton GA, Cranswick NE. Acute suicidality after commencing atomoxetine. J Paediatr Child Health 2008;44:596-8
   PubMed Web of Science ®Google Scholar
• Parretta E, Ianniello B, Ferrazin F, et al. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. Vaccine 2011;29:3708-13
   PubMed Web of Science ®Google Scholar
• Capuano A, Irpino A, Gallo M, et al. Regional surveillance of emergency-department visits for outpatient adverse drug events. Eur J Clin Pharmacol 2009;65:721-8
   PubMed Web of Science ®Google Scholar
• Capuano A, Motola G, Russo F, et al. Adverse drug events in two emergency departments in Naples, Italy: an observational study. Pharmacol Res 2004;50:631-6
   PubMed Web of Science ®Google Scholar
• Wehmeier PM, Schacht A, Lehmann M, et al. Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivity disorder: findings from a patient, parent and physician perspective using items from the pediatric adverse event rating scale (PAERS). Child Adolesc Psychiatry Ment Health 2008;2:11
   PubMedGoogle Scholar
• Patros CH, Hudec KL, Alderson RM, et al. Symptoms of attention-deficit/hyperactivity disorder (ADHD) moderate suicidal behaviors in college students with depressed mood. J Clin Psychol 2013;69:980-93
   PubMed Web of Science ®Google Scholar
• James A, Lai FH, Dahl C. Attention deficit hyperactivity disorder and suicide: a review of possible associations. Acta Psychiatr Scand 2004;110:408-15
   PubMed Web of Science ®Google Scholar
• Impey M, Heun R. Completed suicide, ideation and attempt in attention deficit hyperactivity disorder. Acta Psychiatr Scand 2012;125:93-102
   PubMed Web of Science ®Google Scholar
• Manor I, Gutnik I, Ben-Dor DH, et al. Possible association between attention deficit hyperactivity disorder and attempted suicide in adolescents - a pilot study. Eur Psychiatry 2010;25:146-50
   PubMed Web of Science ®Google Scholar
• Willis CD, McNeil JJ, Cameron PA, Phillips LE. Monitoring drug safety with registries: useful components of postmarketing pharmacovigilance systems. J Clin Epidemiol 2012;65:121-5
   PubMed Web of Science ®Google Scholar